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The KCL037 human embryonic stem cell line was derived from a normal healthy blastocyst donated for research. The
ICMwas isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the derivation
and cell linepropagationwere performed in an animal product-free environment andunder currentGoodManufactur-
ing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Resource table
Name of stem cell line KCL037
Institution King's College London, London UK
Derivation team Neli Kadeva, Victoria Wood, Glenda Cornwell, Stefano
Codognotto, Emma Stephenson
Contact person and email Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date archived/stock date Nov. 21, 2011
Type of resource Biological reagent: cell line
Sub-type Human pluripotent stem cell line
Origin Human embryo
Key marker expression Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60,
TRA-1-81, alkaline phosphatase (AP) activity
Authentication Identity and purity of line conﬁrmed
Link to related literature
(direct URL links and
full references)
1) Jacquet, L., Stephenson, E., Collins, R., Patel, H.,
Trussler, J., Al-Bedaery, R., Renwick, P., Ogilvie, C.,
Vaughan, R., Ilic, D., 2013. Strategy for the creation
of clinical grade hESC line banks that HLA-match a
target population. EMBO Mol. Med. 5 (1), 10–17.
http://dx.doi.org/10.1002/emmm.201201973
http://www.ncbi.nlm.nih.gov/pubmed/23161805
2) Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P.,
Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J.,
Moore, H.D., Murray, H., Kunath, T., 2015. The molec-
ular karyotype of 25 clinical-grade human embryonic
stem cells lines. Sci. Rep. 5, 17,258.
http://www.ncbi.nlm.nih.gov/pubmed/26607962
http://dx.doi.org/10.1038/srep17258
3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L.,
Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S.,
Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude,
P., 2012. Derivation and feeder-free propagation of
human embryonic stem cells under xeno-free condi-
tions. Cytotherapy. 14 (1), 122–128.
http://dx.doi.org/10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
4) Stephenson, E., Jacquet, L., Miere, C., Wood, V.,
Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y.,
Braude, P., Ilic, D., 2012. Derivation and propaga-
tion of human embryonic stem cell lines from fro-
zen embryos in an animal product-free
environment. Nat. Protoc. 7 (7), 1366–1381.
http://dx.doi.org/10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
Information in public
databases
KCL037 is a National Institutes of Health (NIH) registered
hESC line
NIH Registration Number: NIHhESC-14-0269
http://grants.nih.gov/stem_cells/registry/current.
htm?id=675
Ethics The hESC line KCL037 is derived under license from the
UK Human Fertilisation and Embryology Authority
(research license numbers: R0075 and R0133) and also
has local ethical approval (UK National Health Service
Research Ethics Committee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the
experiments conformed to the principles set out in the
WMA Declaration of Helsinki and the NIH Belmont Re-
port. No ﬁnancial inducements are offered for donation.
2. Resource details
Consent signed Sep. 22, 2009
Embryo thawed Oct. 18, 2011
UK Stem Cell Bank Deposit
Approval
Reference:
Sex Male 46, XY
(continued on next page)
Stem Cell Research 16 (2016) 149–151
⁎ Corresponding author.
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Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scr
Grade Clinical
Disease status Healthy/Unaffected
Karyotype (aCGH) Decreased copy number at 2q37.3 and 3q25.1. Both are
considered to be benign copy number variants.
SNP Array Gain on chromosome 18q23 Canham et al. ( 2015)
DNA ﬁngerprint Allele sizes (in bp) of 16 microsatellite markers speciﬁc
for chromosomes 13, 18 and 21 Jacquet et al. (2013)
HLA typing HLA-A 02,03; B 35,40; Bw 06; C 03,04; DRB1 01,13;
DRB3 03; DQB1 05,06 Jacquet et al. (2013) Canham et al.
(2015)
Viability testing Pass
Mycoplasma Negative
Sterility Pass
Pluripotent markers
(immunostaining)
(Fig. 1)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)
Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)
Sibling lines available No
We generated KCL037 clinical grade hESC line following protocols
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed decreased copy number at 2q37.3
(242,930,599–242,948,040) and 3q25.1 (151,368,847–151,542,568).
The imbalances identiﬁed are considered to be benign copy number
variants. The chromosome 3 imbalance was not “called” by software.
Whole-genome single nucleotide polymorphism (SNP) array analy-
sis revealed a 542 kb gain on chromosome 18q23 in KCL037 containing
two coding genes, SALL3 and ATP9B (Canham et al., 2015). A smaller du-
plication (nsv577794) covering the same two genes has been reported
previously (Cooper et al., 2011).
The KCL037 line is conﬁrmed by PCR to be negative for Cytomegalo-
virus (CMV), Human T-Cell Lymphotropic Virus 1 (HTLV1), Human
Immunodeﬁciency Virus 1 (HIV1), Hepatitis C Virus (HepC, HCV),
Hepatitis B Virus (HepB, HBV) and Epstein–Barr virus (EBV), also called
human herpesvirus 4 (HHV4). The testing has been performed by The
Doctors Laboratory London.
We also generated research grade of KCL037 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 – R.4 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Sep. 22, 2009. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 7 – R.4. HFEA
Code of Practice Edition 7 – R.4was in effect: 02Oct. 2008–30 Sep. 2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.
3.4. Viability test
Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.
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3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed in
vitro and in vivo as described (Petrova et al., 2014; Stephenson et al., 2012).
3.7. Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in detail (Ilic et al., 2012).
3.9. SNP array
SNP array was performed as described in detail (Canham et al.,
2015).
3.10. HLA typing
HLA-A,−B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
HLA typing was also performed independently by other group
(Canham et al., 2015).
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Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
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